Biotech company closes heavily oversubscribed financing round

More than 70 investors participated in biotech company Synklino's financing round with proceeds going to the drug development for organ transplant patients infected with the herpesvirus cytomegalovirus (CMV).

Thomas N. Kledal, co-founder and CEO at Synklione (to the right) and John Haurum, chairman of the board of Synklino. | Photo: Synklino / PR

Finding the necessary capital to continue operations has been smooth sailing for biotech company Synklino, which reported on Monday that a financing round has concluded, bringing in DKK 106m (USD 16.2m).

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

China approves Y-mabs drug

Y-mabs’ cancer treatment Danyelza, which is currently licensed to Sciclones, has been approved by the Chinese authorities. Y-mabs will receive double-digit sales royalties.

Further reading

Related articles

Latest news

See all jobs